Medicines Adaptive Pathways to Patients (MAPPs) seek to foster access to beneficial treatments for the right patient groups with high unmet medical needs at the earliest appropriate time in the product life-span in a sustainable fashion . A key component of MAPPs is stakeholder collaboration .
MAPPs is not a rush to expose patients to untested treatments. Clinical data must show that the benefits will very likely outweigh the risks in the defined patient group.
Key questions addressed by ADAPT SMART: